WDNA241220P18000
- 0.00
- 0.000.00%
WISDOMTREE BIOREVOLUTION FUND Newsroom
12 Health Care Stocks Moving In Monday's Pre-Market Session
Novo Nordisk Reportedly Launches Wegovy in China
Analyst Expectations For Natera's Future
Natera Analyst Ratings
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Veracyte Analyst Ratings
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earnings
Twist Bioscience Q4 2024 GAAP EPS $(0.59) Beats $(0.70) Estimate, Sales $84.71M Beat $82.20M Estimate
Earnings Scheduled For November 18, 2024
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
What kind of company is Natera, the largest hold positions of Drew Miller?
Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Shares of Pharmaceutical Companies Are Trading Lower After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.